SFX by Ex Libris Inc.

Title:	Biopharmaceutical benchmarks 2018
Source:	Nature Biotechnology [1087-0156] Walsh, Gary yr:2018

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Kesik Brodacka, M. "Progress in biopharmaceutical development." Biotechnology and applied biochemistry 65.3 (2017): 306-322.
description	2.	DeFrancesco, L. "Drug pipeline 3Q18." Nature Biotechnology 36.12 (2018): 1132-1132.
description	3.	Cankorur Cetinkaya, A. "A consensus genome-scale metabolic network reconstruction for Komagataella (Pichia) pastoris." Yeast 32.Suppl. 1 (2015).
description	4.	Lazar, Greg A. "Next generation antibody drugs: pursuit of the 'high-hanging fruit'." Nature reviews. Drug discovery 17.3 (2017): 197-223.
description	5.	Gronemeyer, P. "Trends in Upstream and Downstream Process Development for Antibody Manufacturing." Bioengineering 1.4 (2014): 188-212.
description	6.	Zhu, J. "Mammalian cell protein expression for biopharmaceutical production." Biotechnology advances 30.5 (2011): 2011-1170.
description	7.	Shima, M. "Emicizumab prophylaxis overcomes factor VIII inhibitors in Hemophilia A." The journal of pediatrics 190 (2017): 287-290.
description	8.	Beck, A. "Strategies and challenges for the next generation of antibody–drug conjugates." Nature reviews. 16.5: 315-337.
description	9.	Jozala, Angela F. "Biopharmaceuticals from microorganisms: from production to purification." Brazilian Journal of Microbiology 47.Suppl 1 (2016): 51-63.
description	10.	Ramasamy, Sri V. "Life cycle assessment as a tool to support decision making in the biopharmaceutical industry: Considerations and challenges." Food and bioproducts processing 94 (2014): 297-305.
description	11.	Berlec, A. "Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells." Journal of industrial microbiology & biotechnology 40.3-4 (2013): 257-274.
description	12.	Werner, Rolf G. "Economic aspects of commercial manufacture of biopharmaceuticals." Journal of biotechnology 113.1-3 (2004): 171-182.
description	13.	Prabhu, Ashish A. "Medium optimization for high yield production of extracellular human interferon-γ from Pichia pastoris: A statistical optimization and neural network-based approach." The Korean journal of chemical engineering 34.4: 1109-1121.
description	14.	"Diversifying clinical trials." Nature Medicine 24.12 (2018): 1779-1779.
description	15.	Sabado, Rachel L. "Dendritic cell-based immunotherapy." Cell Research 27.1 (2017): 74-95.
description	16.	Sause, William E. "Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections." Trends in pharmacological sciences 37.3 (2015): 231-241.
description	17.	Li, F. "Cell culture processes for monoclonal antibody production." mAbs 2.5 (2010): 466-479.
description	18.	Shire, Steven J. "Formulation and manufacturability of biologics." Current opinion in biotechnology 20.6 (2009): 708-714.
description	19.	Rodriguez, J. "Enhanced production of monomeric interferon-ss by CHO cells through the control of culture conditions." Biotechnology progress 21.1 (2005): 22-30.
description	20.	Schugerl, K. "Integrated processing of biotechnology products." Biotechnology advances 18.7 (2000): 581-599.